Literature DB >> 12471628

BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk.

Annika Auranen1, Amanda B Spurdle, Xiaoqing Chen, Julian Lipscombe, David M Purdie, John L Hopper, Adele Green, Catherine S Healey, Karen Redman, Alison M Dunning, Paul D Pharoah, Douglas F Easton, Bruce A J Ponder, Georgia Chenevix-Trench, Karen L Novik.   

Abstract

The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case-control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04-1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17-2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12471628     DOI: 10.1002/ijc.10814

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.

Authors:  Jonathan Beesley; Susan J Jordan; Amanda B Spurdle; Honglin Song; Susan J Ramus; Suzanne Kruger Kjaer; Estrid Hogdall; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

Review 2.  Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  David J Hughes
Journal:  Fam Cancer       Date:  2008-02-19       Impact factor: 2.375

3.  Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes.

Authors:  Deirdre A Hill; Sophia S Wang; James R Cerhan; Scott Davis; Wendy Cozen; Richard K Severson; Patricia Hartge; Sholom Wacholder; Meredith Yeager; Stephen J Chanock; Nathaniel Rothman
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

4.  Association of follicular lymphoma risk with BRCA2 N372H polymorphism in Slovak population.

Authors:  Ján Salagovič; Lucia Klimčáková; Denisa Ilenčíková; Adriana Kafková
Journal:  Med Oncol       Date:  2011-04-08       Impact factor: 3.064

5.  Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.

Authors:  Alice J Sigurdson; Michael Hauptmann; Nilanjan Chatterjee; Bruce H Alexander; Michele Morin Doody; Joni L Rutter; Jeffery P Struewing
Journal:  BMC Cancer       Date:  2004-03-12       Impact factor: 4.430

6.  Consortium analysis of 7 candidate SNPs for ovarian cancer.

Authors:  Susan J Ramus; Robert A Vierkant; Sharon E Johnatty; Malcolm C Pike; David J Van Den Berg; Anna H Wu; Celeste Leigh Pearce; Usha Menon; Aleksandra Gentry-Maharaj; Simon A Gayther; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Honglin Song; Douglas F Easton; Paul D P Pharoah; Montserrat Garcia-Closas; Stephen Chanock; Jolanta Lissowska; Louise Brinton; Kathryn L Terry; Daniel W Cramer; Shelley S Tworoger; Susan E Hankinson; Andrew Berchuck; Patricia G Moorman; Joellen M Schildkraut; Julie M Cunningham; Mark Liebow; Susanne Krüger Kjaer; Estrid Hogdall; Claus Hogdall; Jan Blaakaer; Roberta B Ness; Kirsten B Moysich; Robert P Edwards; Michael E Carney; Galina Lurie; Marc T Goodman; Shan Wang-Gohrke; Silke Kropp; Jenny Chang-Claude; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Ellen L Goode
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

7.  Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient.

Authors:  Teena Bhatla; Smita Dandekar; Benjamin Y Lu; Jinhua Wang; Eugenia Han; Danielle Bitterman; Courtney L Jones; Nikki A Evensen; Margret Magid; Julia A Meyer; William L Carroll
Journal:  J Pediatr Hematol Oncol       Date:  2016-01       Impact factor: 1.289

8.  A common missense variant in BRCA2 predisposes to early onset breast cancer.

Authors:  Bohdan Górski; Steven A Narod; Jan Lubinski
Journal:  Breast Cancer Res       Date:  2005-10-24       Impact factor: 6.466

9.  Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.

Authors:  Domenico Palli; Mario Falchetti; Giovanna Masala; Ramona Lupi; Francesco Sera; Calogero Saieva; Cristina D'Amico; Marco Ceroti; Piera Rizzolo; Maria Adelaide Caligo; Ines Zanna; Laura Ottini
Journal:  BMC Cancer       Date:  2007-09-03       Impact factor: 4.430

10.  Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.

Authors:  Chunqiao Q Tian; Kathleen M Darcy; Thomas C Krivak; Julie A Deloia; Deborah Armstrong; Warren Davis; Hua Zhao; Kirsten Moysich; Christine B Ambrosone
Journal:  Front Oncol       Date:  2013-08-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.